

Special Issue

Immune Checkpoint Regulation and Signaling Pathways in Cancer

Message from the Guest Editor

This Special Issue, titled “Immune Checkpoint Regulation and Signaling Pathways in Cancer”, presents innovative research that tackles these significant concerns. It examines the molecular processes regulating immune checkpoint expression, the intricate interplay between tumor cells and the immune system, and novel therapeutic approaches for cancers resistant to checkpoint suppression.

Our objective in assembling this Special Issue is to present a thorough examination of the present research landscape regarding immunological checkpoints in cancer biology and treatment, while also highlighting potential pathways that may result in next-generation immunotherapies.

This Special Issue will be a crucial resource for researchers, clinicians, and students aiming to enhance their comprehension of immune checkpoint biology and investigate the most recent advancements in cancer immunotherapy. As we persist in elucidating novel aspects of immune modulation inside the tumor microenvironment, we are hopeful that these revelations may facilitate the development of more efficacious and enduring therapies for cancer patients globally.

Guest Editor

Dr. Sreeja C. Sekhar

Department of Pathology, University of Michigan, 1600 Huron Parkway,
Ann Arbor, MI 48109, USA

Deadline for manuscript submissions

31 October 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/235968

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).